Menten AI, Inc.

Menten AI is a biotechnology company that specializes in generative AI for the de novo design of peptide macrocycle therapeutics. Its proprietary platform, MAUD 1.0 (Multi-parametric AI for Unbiased Design), integrates generative machine learning with physics-based models and quantum simulations. This approach enables the design of cyclic peptides from scratch, specifically targeting complex drug interactions such as protein-protein interfaces that are traditionally difficult to address with small molecules or biologics. Unlike standard screening methods, the technology employs physics-informed reinforcement learning to perform multi-parameter optimization, which allows for the efficient creation of molecules with drug-like properties, including oral bioavailability and cell permeability.

The platform is designed to accelerate preclinical drug discovery and help pharmaceutical partners tackle challenging medical targets. By enabling the rapid generation and optimization of potent, permeable, and selective peptides, Menten AI aims to expand the accessible chemical space for drug development. The company has engaged in research collaborations with top-tier pharmaceutical leaders, such as Bristol Myers Squibb, to apply its platform to real-world drug discovery pipelines. Menten AI maintains an active role in the biotechnology sector, presenting its technical advancements at international conferences and participating in industry networks to advance the development of next-generation peptide medicines.